2025-10-11 - Analysis Report
Okay, here's an analysis of Schrodinger Inc. (SDGR) based on the data provided, presented in English with a focus on key metrics and insights.

**Report on Schrodinger Inc. (SDGR)**

Schrodinger Inc. (SDGR) is a company that develops software for drug discovery and materials science.

**1. Performance vs. S&P 500 (VOO)**

*   **Cumulative Return (SDGR):** -53.61%
*   **Cumulative Return (VOO):** 67.24%
*   **Relative Divergence:**
    *   Current: -118.0
    *   Max: 42.2
    *   Min: -120.7
    *   Relative Position: 1.7

**Analysis:** SDGR has significantly underperformed the S&P 500 (VOO) over the period examined. The current relative divergence of -118.0 indicates substantial underperformance, and the relative position of 1.7 suggests it's near the bottom of its historical divergence range.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD   | Alpha  | Beta   | Cap(B) |
|------------|---------|-------|--------|--------|--------|
| 2020-2022  | -70.0%  | 78.2% | -76.0% | 0.0    | 1.4    |
| 2021-2023  | -57.0%  | 81.0% | -59.0% | -0.0   | 2.6    |
| 2022-2024  | 6.0%    | 81.0% | -14.0% | -0.0   | 1.4    |
| 2023-2025  | -2.0%   | 82.6% | -65.0% | -0.0   | 1.4    |

**Analysis:**

*   **CAGR:** The Compounded Annual Growth Rate is negative for most periods, except for 2022-2024.
*   **MDD:** The Maximum Drawdown is consistently high, indicating significant volatility and risk.
*   **Alpha:** The Alpha is negative across all periods, suggesting the stock has underperformed its benchmark on a risk-adjusted basis.
*   **Beta:** Beta is very close to zero across all periods, suggesting the stock has very low correlation with the overall market.
*   **Cap(B):** The market capitalization is in the billions, suggesting the company is a mid-cap company.

**2. Recent Price Action**

*   **Current Price:** 19.32
*   **Last Market Data:** Price: 19.315, Previous Close: 20.65, Change: -6.46%
*   **5-day Moving Average:** 20.416
*   **20-day Moving Average:** 19.7422
*   **60-day Moving Average:** 19.9729

**Analysis:** The current price is below all the moving averages, indicating a short-term downtrend. The significant change of -6.46% in the last market session suggests recent negative price pressure.

**3. Technical Indicators and Expected Return**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 49.19
*   **PPO:** 0.2361
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (47 shares - Very Safe - MRI:0.90) Monthly invest 1.4% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-10-01)
*   **Recent (20-day) Relative Divergence Change:** -1.5 (Negative - indicating short-term decline)
*   **Expected Return (%):** -3570.0% (Long-term, relative to S&P 500)

**Analysis:**

*   Despite the high MRI suggesting investment, the negative expected return of -3570.0% suggests extreme caution for long-term investment.
*   The RSI is close to neutral, suggesting neither overbought nor oversold conditions.
*   The negative change in relative divergence supports the short-term downtrend.

**4. Recent News & Significant Events**

*   **[2025-09-18]** Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
*   **[2025-09-11]** Evaluating Valuation as Market Sentiment Remains Quiet
*   **[2025-09-09]** Potential to Rally 40.43% (Analyst Expectation)
*   **[2025-08-27]** Presentation at Morgan Stanley Global Healthcare Conference
*   **[2025-08-14]** Discontinuation of SGR-2921 Program

**Analysis:** The news is mixed. Analyst expectations of a potential rally are positive, but the discontinuation of a program is concerning.  The valuation evaluation suggests uncertainty.

**4-2. Analyst Opinions**

*   **Consensus:** Buy (~1.56)
*   **Opinions:** 10
*   **Target Price:** Avg: 27.00 / High: 33.00 / Low: 19.00
*   **Recent Rating Changes:** Not provided.

**Analysis:** The analyst consensus is 'Buy' with a significant upside potential based on the average target price.  However, the low target price is near the current trading price.

**5. Recent Earnings Analysis**

| Date       | EPS   | Revenue   |
|------------|-------|-----------|
| 2025-08-06 | -0.59 | 0.05 B$   |
| 2025-05-07 | -0.82 | 0.06 B$   |
| 2024-11-12 | -0.52 | 0.04 B$   |
| 2024-07-31 | -0.74 | 0.05 B$   |
| 2025-08-06 | -0.74 | 0.05 B$   |

**Analysis:**  The company is consistently reporting negative EPS, indicating losses.  Revenue has been relatively stable, but not enough to offset expenses.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-06-30 | $0.05B    | 47.77%        |
| 2025-03-31 | $0.06B    | 52.26%        |
| 2024-12-31 | $0.09B    | 72.61%        |
| 2024-09-30 | $0.04B    | 50.24%        |
| 2024-06-30 | $0.05B    | 66.20%        |

**Capital and Profitability:**

| Quarter    | Equity    | ROE     |
|------------|-----------|---------|
| 2025-06-30 | $0.34B    | -12.59% |
| 2025-03-31 | $0.37B    | -16.01% |
| 2024-12-31 | $0.42B    | -9.54%  |
| 2024-09-30 | $0.45B    | -8.49%  |
| 2024-06-30 | $0.47B    | -11.40% |

**Analysis:** Revenue is modest, with fluctuations.  Profit margins are positive but not enough to drive profitability.  Equity is declining, and the Return on Equity (ROE) is negative, reflecting poor profitability relative to shareholder equity.

**7. Overall Summary**

Schrodinger Inc. (SDGR) presents a mixed picture.

*   **Negative:**  The stock has significantly underperformed the S&P 500.  The company is consistently losing money (negative EPS and ROE).  The long-term expected return is extremely negative. Recent price action is weak.
*   **Positive:**  Analysts have a 'Buy' consensus with significant upside potential. The Market Risk Indicator suggests it is a high investment opportunity. Profit margins are positive.

**Conclusion:**

While analysts are optimistic and the MRI suggests investment, the significant underperformance, negative earnings, declining equity, and negative expected return warrant caution.  The positive analyst ratings and MRI might be based on the company's future potential, but the current financials and market performance indicate substantial risk. Investors should carefully weigh the potential rewards against the very real risks before investing in SDGR. The recent news is mixed and requires further investigation to assess its impact on the company's future prospects.
